Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. develops healthcare technology for chronic low back pain through Nociscan, a cloud-based SaaS platform that uses magnetic resonance spectroscopy, biomarkers, signal processing and augmented intelligence algorithms to help physicians evaluate painful and nonpainful lumbar discs.
Company news commonly covers Nociscan adoption, clinical-site additions, commercial agreements with spine practices and academic medical centers, reimbursement activity, intellectual-property updates for AI-enabled workflows, and operating results. Updates also include capital actions and governance items tied to Aclarion’s Nasdaq-listed common stock and warrants.
Aclarion (Nasdaq: ACON) entered an agreement with the Institute of Neuro Innovation (INI) in Los Angeles, expanding access to its Nociscan platform for chronic low back pain patients.
The collaboration will generate real-world evidence combining Nociscan’s pain-related chemical biomarker data with SPECT-CT bone metabolic information, supporting Aclarion’s scalable growth strategy and payer and provider adoption. Nociscan is described as a SaaS tool that helps distinguish painful from nonpainful lumbar discs and has demonstrated a 97% surgical success rate when all Nociscan-positive discs are treated.
Aclarion (Nasdaq:ACON) reported that its Nociscan MRS technology was used in an NIH-funded, ISSLS Best Paper Award study on chronic low back pain with Modic type 1 changes.
By measuring intradiscal propionic acid, researchers identified immune-linked patient subgroups, suggesting potential Nociscan uses beyond surgical decision support in precision spine care.
Aclarion (Nasdaq: ACON) responded to Echo Lake Capital’s unsolicited offer to acquire the company for $4.00 per share in cash plus contingent value rights. The Board will carefully evaluate the proposal and has also authorized a share repurchase program, citing conviction in Aclarion’s long-term opportunity.
Summary not available.
Aclarion (Nasdaq: ACON, ACONW) added Lanman Spinal Neurosurgery in Beverly Hills as the first private-practice site for its 300-patient CLARITY randomized trial of Nociscan for discogenic chronic low back pain. The trial's primary endpoint is 12-month change in 100mm VAS Back; early interim results are expected to be publicly disclosed in Q4 2026.
Nociscan is described as a SaaS MR spectroscopy solution that quantifies chemical biomarkers and is reported to show a 97% surgical success rate when all Nociscan-positive discs are treated.
Aclarion (Nasdaq: ACON, ACONW) granted an inducement stock option to Daniel Keefe, its new Commercial Director, Western U.S., to purchase 17,000 shares on May 5, 2026. The option exercise price is $3.20 per share, equal to the closing price on the grant date.
One-fourth vests after one year; remaining options vest monthly over three years. The option term is ten years and was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Keefe joining the company.
Aclarion (Nasdaq: ACON, ACONW) announced a second commercial agreement with Weill Cornell Medicine to expand clinical use of its Nociscan platform in a prospective randomized trial led by Roger Härtl, MD (IRB Protocol No. 24-09027977). The study will assess lumbar microdiscectomy with or without intradiscal bone marrow aspirate concentrate (BMAC) over two years, measuring patient-reported outcomes, intervertebral disc health, and pain biomarkers. Aclarion says Nociscan quantifies chemical biomarkers linked to disc pain and reports a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated.
Aclarion (NASDAQ:ACON) reported Q1 2026 results showing accelerating adoption of its Nociscan platform. Key metrics: scan volume +196% YoY and +64% sequential. The company holds $19.0M cash, no debt, 64 issued/pending patents, and announced a $2.5M share repurchase.
Clinical and commercial catalysts include payer reimbursements in the U.K., seven ongoing trials, and an interim CLARITY readout expected for public disclosure in late 2026. Cash runway is projected into H2 2027 on current plans.
Aclarion (Nasdaq: ACON, ACONW) appointed Daniel Keefe as Commercial Director, Western U.S., to lead regional commercial expansion and support continued adoption of Nociscan.
The hire accompanies reported triple-digit utilization growth and cites a 97% surgical success rate when all Nociscan-positive discs are treated, highlighting clinical uptake and commercial momentum.
Aclarion (Nasdaq: ACON) announced a $2.5 million stock repurchase program authorized by its board on April 22, 2026. The company expects to execute repurchases over the next 12 months, funded with existing cash and cash equivalents, subject to market conditions and legal rules.
As of March 31, 2026, Aclarion reported approximately $19.0 million in cash and cash equivalents and said the cash runway supports operations through near-term milestones, including the CLARITY randomized trial.